Second line therapy for patients with type 2 diabetes should favour newer agents over addition of a sulphonylurea to metformin, an observational study suggests. In a three year follow-up of patients with T2D initiating second‐line glucose‐lowering therapy, metformin in combination with a DPP‐4 inhibitor, an SGLT‐2 inhibitor or a GLP‐1 receptor agonist showed significant benefits ...
Type 2 diabetes
Sulphonylureas no longer favoured as second line therapy in T2D
By Michael Woodhead
5 May 2021